Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
The Best 10 Innovation Developments of the Year - 2Check out the exclusive pitch deck Valerie Health used to raise $30 million from Redpoint Ventures to automate healthcare faxes
- 3Eleven arrested over mass shooting in South Africa tavern
- 4'I carried my wife's body for an hour and a half' - BBC hears stories of protesters killed in Iran
- 57 Logically Demonstrated Techniques for Better Rest
- Denny's is shutting down restaurants around the country. What's behind the closures?
- Vote In favor of Your Favored Kind Of Bites
- Want to be better about saving money in 2026? Try these money-saving tips for having a ‘low-buy’ January and beyond
- Computerized Domains d: A Survey of \Vivid Undertakings\ Computer generated Reality Game
- Strength training is crucial after menopause. How to make the most of your workouts
- Who plays Moana in the live-action remake? What to know about Catherine Lagaʻaia.
- Rediscovering Experience Through Excursions: Individual Travel Stories
- How to watch 'A Charlie Brown Christmas' for free this weekend
- An Extended time of Careful Nurturing: Individual Bits of knowledge on Bringing up Youngsters
